Alphascreen cgmp phosphodiesterase assay using alphascreen cgmp supplement with anti-cgmp antibody

ALPHASCREEN GUANYLA
AlphaScreen cGMP Phosphodiesterase AssayUsing AlphaScreen cGMP Supplement with Anti-cGMP Antibody TION NOTE
TE CYCLASES
Figure 1. Principle of the AlphaScreen cGMP PDE assay. The cGMP PDE enzyme depletesthe unlabeled cGMP competitor, allowing the two AlphaScreen beads to bind via the anti-cGMP antibody interaction. As a result, an intense AlphaScreen signal is generated. Introduction
second form is of cytosolic nature2.
w w w. p e r k i n e l m e r. c o m
* Please note that for compound screening purposes, we recommend adding 0.5 µLof test compounds to 4.5 µL of cGMP Materials and methods
reaction Buffer. If the test compounds are Results and discussion
Figure 2. Titration of enzyme and substrate in the PDE assay using a detection time of 2 hours. confirming the stability of the assay.
Figure 3. Time Course of PDE enzymatic activity. Left panel: AlphaScreen Signal (cps); Right Panel: amount of cGMP hydrolyzed (pmoles) Figure 4. Inhibition Curves for PDE V w w w. p e r k i n e l m e r. c o m
References
1) Ghalayini IF, ATP-regulated
module (ARM) of the atrial
natriuretic factor receptor
Conclusion
guanylate cyclase, Int J Impot
Nitric oxide-cyclic GMP path-
way with some emphasis on
cavernosal contractility,
Peptides 2005 Jun;26(6):969-84.
A Simple Statistical Parameter
for Use in Evaluation and
Validation of High Throughput
Screening Assays,
J Biomol Screen Apr 1999; 4: 67-73.
Corbin JD, Inhibition of Cyclic
GMP-Binding Cyclic GMP-
Specific Phosphodiesterase
(Type 5) by Sildenafil and
Related Compounds, Mol
Pharmacol 1999 Jul; 56(1):124-30.
Cyclic GMP Phosphodiesterase
Inhibitors. 2. Requirement of
6-Substitution of Quinazoline
Derivatives for Potent and
Selective Inhibitory Activity,
Figure 5. Screening validation of AlphaScreen cGMP PDE assay. Representative Z’ graph for a 384 manual assay. PerkinElmer Life and
Analytical Sciences
710 Bridgeport Avenue
Shelton, CT 06484-4794 USA
Phone: (800) 762-4000 or
(+1) 203-925-4602
www.perkinelmer.com
For a complete listing of our global offices, visit www.perkinelmer.com/lasoffices
2006 PerkinElmer, Inc. All rights reserved. The PerkinElmer logo and design are registered trademarks of PerkinElmer, Inc. Fusion␣ is a trademark and AlphaScreen and EnVision areregistered trademarks of PerkinElmer, Inc. or its subsidiaries, in the United States and other countries. All other trademarks not owned by PerkinElmer, Inc. or its subsidiaries that aredepicted herein are the property of their respective owners. PerkinElmer reserves the right to change this document at any time without notice and disclaims liability for editorial, pictorialor typographical errors.

Source: http://www.perkinelmer.de/CMSResources/Images/44-73018APP_AlphaScreencGMPPhosphodiestrase.pdf